roundtable takeaways, part 2: long-term outcomes of vegf-inhibitor use in amd management
Published 4 years ago • 7 plays • Length 0:27Download video MP4
Download video MP3
Similar videos
-
1:02
the current state of research on long-term vegf inhibitor use
-
4:35
targeting vascular endothelial growth factor (vegf) in cancer!
-
2:03
investigating the role of vegf in targeted therapy for cancer
-
0:15
anti vegf treatment for amd
-
1:03:04
vegf and anti-vegf in eye disease
-
26:17
brolucizumab new, stronger, longer acting anti vegf the current clinical evidence - dr. adrian koh
-
1:03:30
more than what you eat: regulation of metabolic health and aging by diet composition and activity
-
56:50
anti vegf treatments for eye disease
-
8:38
vegf to extend lifespan? (targeting vascular aging)
-
0:57
combined inhibition of parp and vegf in gastric cancer
-
0:53
dr. chan discusses the vegf-trap agent aflibercept
-
4:22
vegf and egfr pathways in detail: target for new therapies against cancer
-
1:32
vegf blood marker
-
1:48
vegf in alzheimer's disease
-
4:36
which anti-vegf treatment regimen?
-
0:32
amd 03 vegf shorter
-
11:21
opthea: opt-302 (vegf-c/d trap) for combination treatment in namd and dme
-
4:17
blocking vegfr2 vs vegfa or vegfb in lung cancer
-
4:24
vegf inhibition in nsclc
-
1:28
how to eat more and weigh less | eat plants feel whole cookbook
-
7:32
opthea eye phase iib trial in 2017 (ois@aao 2016)